苹果(AAPL.O)CEO库克：今年将在德克萨斯州开设先进的服务器制造工厂。 ...

Core Points - Kimberly-Clark Corporation will establish an $800 million advanced manufacturing facility in Trumbull County, Ohio, creating 491 new high-quality jobs [1][4][11] - This facility will be Kimberly-Clark's first investment in Ohio and is part of a strategic expansion to enhance its operations in the American market [3][4] - The project received a 10-year Job Creation Tax Credit from the Ohio Tax Credit Authority, which was approved earlier this week [2] Company Overview - Kimberly-Clark is a leading manufacturer of personal care and hygiene products, with a portfolio that includes brands such as Huggies, Kleenex, and Scott, and operates in over 175 countries [6] - The new facility will span over one million square feet and is expected to serve approximately 117 million consumers in the Midwest and Northeast [4][6] Economic Impact - The investment is anticipated to have a long-term economic impact on the region, not only by creating direct jobs but also by attracting ancillary businesses and boosting local housing and economy [11][12] - The project is seen as a catalyst for regional revitalization and reflects Ohio's pro-business climate and commitment to workforce development [7][11] Collaboration and Support - The successful establishment of the facility is attributed to close collaboration among local, regional, and state partners, including JobsOhio and the Ohio Department of Development [8][10] - The site received $17.2 million from the All Ohio Future Fund to assist in site readiness and infrastructure development [5]

Pre-market futures are up this morning, though somewhat muted from levels prior to economic reports out this morning on unemployment claims. We also see a full compliment of Q1 earnings reports ahead of today’s opening bell, with another couple “Mag 7” companies due to report after today’s close.Jobless Claims Jump Higher Last WeekFor months, we’ve been talking in this space about the steadiness and resiliency of weekly unemployment claims. While other metrics on the economy and employment have begun to sho ...

earnings conference call second quarter fiscal 2025 May 1, 2025 — Forward-Looking Statements — This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Ashland has identified some of these forward-looking statements with words such as "anticipates," "believes," "expects," "estimates," "is likely," "predicts," "projects," "forecasts," "objectives," "may," "will," "shoul ...

Core Insights - Lexeo Therapeutics, Inc. is presenting new data on its AAV manufacturing approach at the upcoming ASGCT meeting, highlighting advancements in production efficiency and quality [1][2] - The company has optimized a manufacturing platform that enhances scalability, reduces costs, and maintains the purity and potency of AAV products, which is crucial for its clinical-stage gene therapy programs [2] Company Overview - Lexeo Therapeutics is a clinical stage genetic medicine company based in New York City, focused on innovative treatments for cardiovascular diseases [3] - The company is developing therapeutic candidates targeting genetic causes of conditions such as Friedreich ataxia cardiomyopathy and plakophilin-2 arrhythmogenic cardiomyopathy, addressing significant unmet medical needs [3] Presentation Details - Lexeo will present two key abstracts at the ASGCT meeting: - "Improving VP1 Ratios Impact on CQAs in rh10 AAV Manufactured through Sf9 Platform" on May 13, 2025 [2] - "Development of a Novel High-Yielding Scalable Sf9-Baculovirus Platform to Produce Quality AAV at 200L Scale" on May 15, 2025 [2]

INVESTOR PRESENTATION All company names are trademarks , registered® trademarks or service marks of their respective holders. Use of them does not imply any affiliation with or endorsement of them. 2 LXPINDUSTRIAL TRUST FIRST QUARTER 2025 LXPINDUSTRIAL TRUST Forward-Looking Statements and Other Disclosure This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended ...

Core Insights - Exco Technologies Limited reported solid results for Q2 fiscal 2025, with consolidated sales of $166.1 million, a 1% increase from $163.8 million in the same quarter last year [2][5] - The company announced a quarterly dividend of $0.105 per common share, to be paid on June 30, 2025 [1] Financial Performance - Net income for Q2 was $6.4 million, down from $8.1 million in the same quarter last year, representing a 21% decrease [7] - Earnings per share (EPS) were reported at $0.17, including $0.05 in restructuring charges [5][7] - EBITDA for the quarter totaled $19.7 million, a decrease of 7% from $21.2 million in the prior year [11] Segment Performance - The Automotive Solutions segment reported sales of $82.9 million, a decrease of 3% year-over-year, but a sequential increase of 15% [3] - The Casting and Extrusion segment saw sales of $83.2 million, an increase of 7% from the same period last year [4] Market Conditions - Global trade uncertainty has led the company to withdraw its Fiscal 2026 financial targets, although management remains optimistic about long-term growth opportunities [2][14] - The automotive market is facing challenges due to tariff uncertainties, recession risks, and environmental regulations, but there are supportive factors such as lower interest rates and an aging vehicle fleet [3][14] Strategic Initiatives - Exco is focusing on strategic investments and new program launches to capitalize on growth opportunities [14] - The company is developing its greenfield locations in Morocco and Mexico to gain market share in Europe and Latin America [6][15] Cash Flow and Capital Expenditures - Exco generated cash from operating activities of $8.7 million and free cash flow of $3.1 million in the quarter [12] - The company invested $4.1 million in growth capital expenditures during the quarter [12]

Core Insights - Ashland Inc. reported a mixed performance in Q2 FY2025, with sales of $479 million, a 17% decrease from $575 million in the prior year, primarily due to portfolio optimization initiatives [4][21][23] - The company revised its full-year fiscal 2025 outlook, anticipating flattish organic sales volume growth and adjusted EBITDA in the range of $400 million to $420 million [21][23] Financial Performance - Net income for Q2 was $31 million, down from $120 million in the prior year, resulting in diluted earnings per share of $0.63 compared to $2.40 [4][5] - Adjusted EBITDA was $108 million, a 14% decrease from $126 million in the prior year, primarily due to the impact of portfolio optimization and lower organic sales [5][10] - Cash flows from operating activities were $9 million, a decrease from $54 million in the prior-year quarter, with ongoing free cash flow totaling negative $6 million [7][32] Segment Performance - Life Sciences sales totaled $172 million, a 23% decrease year-over-year, primarily due to the divestiture of the Nutraceuticals segment [9][10] - Personal Care sales were $146 million, a 14% decrease, attributed to portfolio optimization and specific customer challenges [11][12] - Specialty Additives reported sales of $134 million, a 15% decrease, driven by portfolio optimization and competitive intensity in export markets [13][14] Cost Management and Optimization - The company has completed its portfolio optimization, which included the sale of Avoca and identified a $30 million cost reduction plan [3][4] - Ashland is focusing on accelerating cost savings from its $60 million manufacturing optimization plans, with early benefits evident in robust EBITDA margins above 30% in Life Sciences and Personal Care [3][4] Tariff and Trade Impact - Ashland is closely monitoring tariff policies and has estimated a tariff impact of $3 to $5 million for the second half of FY2025, increasing to $5 to $7 million annually after mitigation actions [19][20] - The company is implementing strategies to mitigate risks associated with tariffs and global trade policies while focusing on maintaining flexible operations [18][19] Market Outlook - The company anticipates a positive inflection in organic sales volumes in the second half of FY2025, led by Life Sciences, to offset declines experienced in the first half [21][24] - Ashland's strategic priorities include enhancing business mix and improving profitability in response to the evolving demand landscape [22][24]

REDWOOD CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the first quarter of 2025 on Wednesday, May 14, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update. Participants may access ...

ROCK HILL, S.C., April 30, 2025 (GLOBE NEWSWIRE) -- 3D Systems (NYSE:DDD) announced today it will release its financial results for the first quarter 2025 after the U.S. stock markets close on Monday, May 12, 2025. The company will hold a conference call and simultaneous webcast to discuss these financial results on Tuesday, May 13, 2025 at 8:30 a.m. Eastern Time. First Quarter 2025 Financial Results Conference CallDate: Tuesday, May 13, 2025Time: 8:30 a.m. Eastern TimeListen via webcast: www.3dsystems.com/ ...